News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Preliminary Results
Released    07:00 24-Jun-2009
Number     3938U07

FOR IMMEDIATE RELEASE

London, 24 June 2009

PRELIMINARY RESULTS ANNOUNCEMENT
for the year ended 31 December 2008

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce its preliminary results for the year ended 31 December 2008.

Key Highlights:

Lead candidate for the treatment of Lupus, LupuzorTM, licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009
Interim analysis for the Phase IIb study of LupuzorTM has demonstrated statistically significant superiority of LupuzorTM over placebo
Data for IPP-204106 has confirmed the ability of the programme to effectively control and stop the growth of a large panel of human cancer cell lines both "in vitro" and "in vivo"
Awarded €1.15m in grants from prestigious French institutions for the development of the Group's promising cancer compound, IPP-204106
Share placings completed in July 2008 raising £2.7m before deduction of placement costs from UK and Swiss institutional investors.
Strong cash position due to Cephalon deal, share placings and grants awarded

Dimitri Dimitriou, Chief Executive Officer, said: "2008 was a landmark year for ImmuPharma with the successful licensing of LupuzorTM to Cephalon, Inc, successful share placings, bringing in additional blue-chip institutional investors, receipt of prestigious French grants and good progress on our pipeline. We look forward to reporting further progress throughout 2009."

For further information please contact:

ImmuPharma PLC +44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer
Richard Warr, Chairman
Tracy Weimar, Vice President, Operations

Buchanan Communications +44 20 7466 5000

Lisa Baderoon
Rebecca Skye Dietrich

Panmure Gordon & Co 44 151 243 0963

Andrew Burnett / Rakesh Sharma
Ashton Clanfield (Corporate Broking)

Full report and announcement:


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Preliminary Results Released 07:00 24-Jun-2009 Number 3938U07 FOR IMMEDIATE RELEASE London, 24 June 2009 PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2008 ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce its preliminary results for the year ended 31 December 2008. Key Highlights: Lead candidate for the treatment of Lupus, LupuzorTM, licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009 Interim analysis for the Phase IIb study of LupuzorTM has demonstrated statistically significant superiority of LupuzorTM over placebo Data for IPP-204106 has confirmed the ability of the programme to effectively control and stop the growth of a large panel of human cancer cell lines both "in vitro" and "in vivo" Awarded €1.15m in grants from prestigious French institutions for the development of the Group's promising cancer compound, IPP-204106 Share placings completed in July 2008 raising £2.7m before deduction of placement costs from UK and Swiss institutional investors. Strong cash position due to Cephalon deal, share placings and grants awarded Dimitri Dimitriou, Chief Executive Officer, said: "2008 was a landmark year for ImmuPharma with the successful licensing of LupuzorTM to Cephalon, Inc, successful share placings, bringing in additional blue-chip institutional investors, receipt of prestigious French grants and good progress on our pipeline. We look forward to reporting further progress throughout 2009." For further information please contact: ImmuPharma PLC +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman Tracy Weimar, Vice President, Operations Buchanan Communications +44 20 7466 5000 Lisa Baderoon Rebecca Skye Dietrich Panmure Gordon & Co 44 151 243 0963 Andrew Burnett / Rakesh Sharma Ashton Clanfield (Corporate Broking) Full report and announcement: ©2009 London Stock Exchange plc. All rights reserved